一次治疗长期获益?“天价抗癌药”仍需破解商业化难题

猛犸资本局
Yesterday

“细胞与基因治疗(CGT)是近年来兴起的治疗领域,尽管科学研究已有数十年积累,但真正的全球爆发性发展集中在近十年。与传统小分子和大分子药物以蛋白质为靶点不同,CGT靶点范围从理论上可覆盖人类全部约三万个基因,因此具备更广阔的成药想象空间。”在近日举行的第二届中国细胞与基因治疗大会中,中国细胞与基因治疗联盟(CSGCT)联合发起人、君联资本执行董事戚飞在接受时代周报等媒体采访时表示。根据ASGCT(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10